NO20085331L - Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer - Google Patents
Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorerInfo
- Publication number
- NO20085331L NO20085331L NO20085331A NO20085331A NO20085331L NO 20085331 L NO20085331 L NO 20085331L NO 20085331 A NO20085331 A NO 20085331A NO 20085331 A NO20085331 A NO 20085331A NO 20085331 L NO20085331 L NO 20085331L
- Authority
- NO
- Norway
- Prior art keywords
- pyrazolo
- pyrimidines
- cdk inhibitors
- compounds
- cdk
- Prior art date
Links
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 title abstract 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title 1
- 108091007914 CDKs Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80257706P | 2006-05-22 | 2006-05-22 | |
| PCT/US2007/011991 WO2007139732A1 (en) | 2006-05-22 | 2007-05-21 | Pyrazolo [1, 5-a] pyrimidines as cdk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20085331L true NO20085331L (no) | 2009-02-19 |
Family
ID=38544151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20085331A NO20085331L (no) | 2006-05-22 | 2008-12-19 | Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20070275963A1 (pt) |
| EP (1) | EP2027127A1 (pt) |
| JP (1) | JP2009538304A (pt) |
| KR (1) | KR20090019796A (pt) |
| CN (1) | CN101495481A (pt) |
| AR (1) | AR061072A1 (pt) |
| AU (1) | AU2007268083A1 (pt) |
| BR (1) | BRPI0712016A2 (pt) |
| CA (1) | CA2653076A1 (pt) |
| EC (1) | ECSP088906A (pt) |
| IL (1) | IL195238A0 (pt) |
| MX (1) | MX2008014824A (pt) |
| NO (1) | NO20085331L (pt) |
| PE (1) | PE20080071A1 (pt) |
| RU (1) | RU2008150419A (pt) |
| TW (1) | TW200817404A (pt) |
| WO (1) | WO2007139732A1 (pt) |
| ZA (1) | ZA200809796B (pt) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011503084A (ja) * | 2007-11-07 | 2011-01-27 | シェーリング コーポレイション | 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用 |
| SG179083A1 (en) * | 2009-09-11 | 2012-04-27 | Cylene Pharmaceuticals Inc | Pharmaceutically useful heterocycle-substituted lactams |
| WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| EP2699554B1 (en) * | 2011-04-19 | 2016-11-02 | Bayer Intellectual Property GmbH | Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines |
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| US8957078B2 (en) | 2013-03-15 | 2015-02-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| PT3077397T (pt) | 2013-12-06 | 2020-01-22 | Vertex Pharma | Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo |
| WO2015092707A2 (en) | 2013-12-17 | 2015-06-25 | Csir | A method for identification of anti-hiv human mirna mimics and mirna inhibitors and anti-hiv pharmaceutical compounds |
| MX373102B (es) | 2014-06-05 | 2020-04-17 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo. |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| CA3000633C (en) | 2014-10-14 | 2023-10-03 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
| JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| USRE50776E1 (en) | 2015-03-27 | 2026-02-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| RU2633032C1 (ru) * | 2016-05-23 | 2017-10-12 | Общество с ограниченной ответственностью "Новые научные технологии" | Новые ингибиторы серин-треониновых киназ, в том числе для лечения онкологических заболеваний и туберкулеза |
| US20210101881A1 (en) * | 2018-02-12 | 2021-04-08 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Pyrimidine compound, preparation method thereof and medical use thereof |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| US11155560B2 (en) | 2018-10-30 | 2021-10-26 | Kronos Bio, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN111393447B (zh) * | 2020-05-14 | 2021-01-15 | 苏州信诺维医药科技有限公司 | 一种嘧啶并吡唑类化合物、其制备方法及应用 |
| CN117567460A (zh) * | 2022-08-08 | 2024-02-20 | 明慧医药（杭州）有限公司 | 一种前药化合物及其制备方法和用途 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025228376A1 (zh) * | 2024-04-30 | 2025-11-06 | 阿诺医药 (新加坡) 有限公司 | Cyclin K降解剂药物及其抗体偶联物 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| DE60313872T2 (de) * | 2002-09-04 | 2008-01-17 | Schering Corp. | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| MXPA05002571A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| JP5052518B2 (ja) * | 2005-10-06 | 2012-10-17 | シェーリング コーポレイション | プロテインキナーゼインヒビターとしてのピラゾロピリミジン |
| BRPI0616985B1 (pt) * | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
-
2007
- 2007-05-21 WO PCT/US2007/011991 patent/WO2007139732A1/en not_active Ceased
- 2007-05-21 US US11/751,282 patent/US20070275963A1/en not_active Abandoned
- 2007-05-21 RU RU2008150419/04A patent/RU2008150419A/ru not_active Application Discontinuation
- 2007-05-21 MX MX2008014824A patent/MX2008014824A/es unknown
- 2007-05-21 JP JP2009512064A patent/JP2009538304A/ja active Pending
- 2007-05-21 KR KR1020087028392A patent/KR20090019796A/ko not_active Withdrawn
- 2007-05-21 BR BRPI0712016-8A patent/BRPI0712016A2/pt not_active IP Right Cessation
- 2007-05-21 AU AU2007268083A patent/AU2007268083A1/en not_active Abandoned
- 2007-05-21 CA CA002653076A patent/CA2653076A1/en not_active Abandoned
- 2007-05-21 CN CNA2007800280091A patent/CN101495481A/zh active Pending
- 2007-05-21 PE PE2007000617A patent/PE20080071A1/es not_active Application Discontinuation
- 2007-05-21 EP EP07795066A patent/EP2027127A1/en not_active Withdrawn
- 2007-05-22 TW TW096118244A patent/TW200817404A/zh unknown
- 2007-05-22 AR ARP070102207A patent/AR061072A1/es not_active Application Discontinuation
-
2008
- 2008-11-11 IL IL195238A patent/IL195238A0/en unknown
- 2008-11-17 ZA ZA200809796A patent/ZA200809796B/xx unknown
- 2008-11-21 EC EC2008008906A patent/ECSP088906A/es unknown
- 2008-12-19 NO NO20085331A patent/NO20085331L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200809796B (en) | 2009-11-25 |
| BRPI0712016A2 (pt) | 2011-12-27 |
| JP2009538304A (ja) | 2009-11-05 |
| WO2007139732A1 (en) | 2007-12-06 |
| CN101495481A (zh) | 2009-07-29 |
| TW200817404A (en) | 2008-04-16 |
| US20070275963A1 (en) | 2007-11-29 |
| RU2008150419A (ru) | 2010-09-20 |
| KR20090019796A (ko) | 2009-02-25 |
| EP2027127A1 (en) | 2009-02-25 |
| AR061072A1 (es) | 2008-07-30 |
| IL195238A0 (en) | 2009-08-03 |
| CA2653076A1 (en) | 2007-12-06 |
| ECSP088906A (es) | 2008-12-30 |
| AU2007268083A1 (en) | 2007-12-06 |
| MX2008014824A (es) | 2008-12-01 |
| PE20080071A1 (es) | 2008-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20085331L (no) | Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer | |
| NO20082091L (no) | Nye pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer | |
| NO20053144L (no) | Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler. | |
| PH12015500666A1 (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
| MX2009011355A (es) | Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. | |
| MY169791A (en) | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors | |
| MY188335A (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors | |
| WO2004078682A3 (en) | Cyclic compounds and compositions as protein kinase inhibitors | |
| BRPI0720270B8 (pt) | compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida | |
| MX2009003734A (es) | Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina. | |
| MX2009003185A (es) | Pirazolopirimidinas como inhibidores de lipido cinasa pi3k. | |
| SG132683A1 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
| MX2009011950A (es) | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| MX2009003733A (es) | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina. | |
| WO2006106326A8 (en) | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors | |
| WO2009097287A9 (en) | Compounds and compositions as kinase inhibitors | |
| UA95940C2 (uk) | Азаіндоли як інгібітори кіназ януса | |
| BR112012010041A2 (pt) | derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10 | |
| NO20074431L (no) | Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer | |
| GT201000082A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b | |
| SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
| WO2008045267A3 (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
| MX2009004771A (es) | Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa. | |
| MX2009006690A (es) | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |